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I read with interest the article by Lomia and colleagues
wherein they have described the use of carbamazepine for
treatment of moderate and severe persistent asthma.1
However, there are two points regarding the study which
need careful attention.
Firstly, patients with persistent asthma are often receiv-
ing treatment with theophylline or its analogs. In the
current study also, more than two thirds of patients in each
group were on oral theophylline. Carbamazepine has been
shown to interact with theophylline and reduce the half life
of the latter.2,3 In patients with moderate-to-severe
persistent asthma, such an effect can not only result in
worsening of asthma control but also increase the risk of
serious exacerbations, hospitalization and thus an increase
in the morbidity (and possibly mortality) associated with
asthma.
Secondly, carbamazepine itself has been associated with
the development of a wide range of pulmonary disorders
including pulmonary eosinophilia, diffuse parenchymal lung
disease and even respiratory failure.4–7 Occurrence of
asthma has also been reported with the use of carbamaze-
pine.8,9 Since drug hypersensitivity has been the postulated
underlying mechanism, patients have usually been managed
with withdrawal of the drug and administration of corticos-
teroids, although severe cases, wherein administration of
carbamazepine was associated with the development of
respiratory failure, have required mechanical ventilatory
support in addition to other measures.10
The authors’ recommendation for the routine use of
carbamazepine in persistent asthma on the basis of a single
trial involving small number of patients in each group is at
present, premature and unwarranted. It would be prudent
to first evaluate the potential adverse effects associated
with the use of carbamazepine in patients with persistent
asthma by conducting randomized clinical trials (involving
larger patient numbers) that are designed to test the safety
profile of the drug rather than its efficacy. After all, in
the practice of medicine, non maleficence precedes
beneficence.ont matter & 2006 Elsevier Ltd. All rights reserved.
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